Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113236 | 0.80 | MAPT (0.41) | MAPTGAAL3MBTL1FAAHNPSR1 | |
| SCHEMBL2255510 | 0.78 | SOAT1 (0.39) | MAPTGAAFAAHNPSR1GLO1 | |
| SCHEMBL2204826 | 0.78 | ALDH1A1 (0.43) | MAPTGAANPSR1GLO1ALDH1A1 | |
| SCHEMBL10644070 | 0.77 | ALDH1A1 (0.36) | MAPTGAAFAAHNPSR1GLO1 | |
| SCHEMBL16808974 | 0.77 | ALDH1A1 (0.36) | MAPTGAAFAAHNPSR1GLO1 | |
| SCHEMBL885033 | 0.76 | MAPT (0.39) | MAPTGAANPSR1GLO1ALDH1A1 | |
| SCHEMBL17964096 | 0.75 | GAA (0.52) | MAPTGAANPSR1GLO1ALDH1A1 | |
| SCHEMBL4976336 | 0.75 | EGLN1 (0.44) | MAPTGAANPSR1GLO1ALDH1A1 | |
| SCHEMBL17188463 | 0.75 | CES2 (0.41) | MAPTGAAFAAHNPSR1GLO1 | |
| SCHEMBL17194942 | 0.75 | MAPT (0.39) | MAPTGAAL3MBTL1FAAHNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008089005-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | WO | claimed |
| US-20250197381-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-19 | — | — | US | disclosed |
| WO-2025090465-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-05-01 | — | — | WO | disclosed |
| US-12247021-B2 | Substituted tetrahydrofurans as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-03-11 | — | — | US | disclosed |
| EP-4506001-A2 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240391907-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-11-28 | — | — | US | disclosed |
| EP-4069691-B1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2024-09-18 | — | — | EP | disclosed |
| US-11919887-B2 | Substituted tetrahydrofurans as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-03-05 | — | — | US | disclosed |
| US-11834441-B2 | Substituted tetrahydrofurans as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230286961-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2023-09-14 | — | — | US | disclosed |
| EP-4069691-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-114945566-A | Substituted tetrahydrofurans as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20210198241-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-07-01 | — | — | US | disclosed |
| WO-2021113627-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-06-10 | — | — | WO | disclosed |
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
| WO-2008089005-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105665-A1 | RENIN INHIBITORS | REN, ACE, AGT | MAPT 2847/4885GAA 96/4885L3MBTL1 4883/4885 |
| US-12247021-B2 | Substituted tetrahydrofurans as modulators of sodium channels | TRPV1, TRPA1, SCN2B | MAPT 1738/4885GAA 3623/4885L3MBTL1 4266/4885 |
| US-20230286961-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | TRPV1, TRPA1, SCN2B | MAPT 1738/4885GAA 3623/4885L3MBTL1 4266/4885 |
| US-11834441-B2 | Substituted tetrahydrofurans as modulators of sodium channels | TRPV1, TRPA1, SCN2B | MAPT 1738/4885GAA 3623/4885L3MBTL1 4266/4885 |
| US-20210198241-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | TRPV1, TRPA1, SCN2B | MAPT 1738/4885GAA 3623/4885L3MBTL1 4266/4885 |
| US-20240391907-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | TRPV1, TRPA1, SCN2B | MAPT 1738/4885GAA 3623/4885L3MBTL1 4266/4885 |
| US-11919887-B2 | Substituted tetrahydrofurans as modulators of sodium channels | TRPV1, TRPA1, SCN2B | MAPT 1738/4885GAA 3623/4885L3MBTL1 4266/4885 |
| US-20250197381-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | TRPV1, TRPA1, SCN2B | MAPT 1738/4885GAA 3623/4885L3MBTL1 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.